Latest news with #WATCHMAN
Yahoo
5 days ago
- Business
- Yahoo
BSX Q2 Deep Dive: Cardiovascular Momentum, New Technologies, and Global Expansion Shape Outlook
Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 22.8% year on year to $5.06 billion. Guidance for next quarter's revenue was optimistic at $4.97 billion at the midpoint, 2.2% above analysts' estimates. Its non-GAAP profit of $0.75 per share was 4.1% above analysts' consensus estimates. Is now the time to buy BSX? Find out in our full research report (it's free). Boston Scientific (BSX) Q2 CY2025 Highlights: Revenue: $5.06 billion vs analyst estimates of $4.89 billion (22.8% year-on-year growth, 3.4% beat) Adjusted EPS: $0.75 vs analyst estimates of $0.73 (4.1% beat) Adjusted EBITDA: $1.51 billion vs analyst estimates of $1.43 billion (29.8% margin, 5.3% beat) Revenue Guidance for Q3 CY2025 is $4.97 billion at the midpoint, above analyst estimates of $4.86 billion Management raised its full-year Adjusted EPS guidance to $2.97 at the midpoint, a 2.2% increase Operating Margin: 16.2%, up from 12.6% in the same quarter last year Organic Revenue rose 17.4% year on year (14.7% in the same quarter last year) Market Capitalization: $159.4 billion StockStory's Take Boston Scientific's second quarter results reflected broad-based strength, with operational sales rising sharply and organic growth notably outpacing the company's underlying market rates. Management attributed the quarter's outperformance to the Cardiovascular segment, particularly the rapid adoption of FARAPULSE for atrial fibrillation and the sustained momentum of the WATCHMAN device. CEO Michael Mahoney highlighted that the 'reliability and trust that the physician community and referring physicians have in [WATCHMAN], along with our clinical and sales team, is driving that.' The company also cited double-digit growth in several international markets and ongoing commercial execution as key contributors to strong top-line and adjusted profitability. Looking ahead, Boston Scientific's updated guidance is grounded in expectations for continued expansion in core cardiovascular therapies, additional product launches, and further international market penetration. Management emphasized that ongoing investments in research and development, as well as anticipated regulatory approvals for devices such as the EMPOWER leadless pacemaker and expanded indications for FARAPULSE, are set to support the company's growth trajectory. CFO Jonathan Monson stated, 'We now expect to expand full year adjusted operating margin by 75 to 100 basis points while increasing our level of investment in R&D to fuel durable, differentiated revenue growth.' Key Insights from Management's Remarks Management pointed to product innovation and market adoption in cardiovascular therapies as the primary drivers of recent performance, while also addressing operational challenges from product discontinuations and tariffs. Cardiovascular growth surge: The Cardiovascular segment led company growth, fueled by strong demand for FARAPULSE (a pulsed field ablation system for atrial fibrillation) and robust performance of the WATCHMAN left atrial appendage closure device. New labeling and expanded indications, particularly in Japan and the U.S., supported broader adoption. WATCHMAN and concomitant procedures: WATCHMAN's uptake was enhanced by the trend toward concomitant procedures, where atrial fibrillation ablation and appendage closure are performed together. Over 60% of U.S. electrophysiologists using WATCHMAN are adopting this approach, following recent clinical data and reimbursement changes. Management expects ongoing growth as clinical evidence and payer support evolve. Impact of product discontinuation: The global discontinuation of the ACURATE valve led to inventory write-downs and pressured gross margins. However, management highlighted that strong revenue growth and 'spend control' offset these headwinds, keeping full-year margin guidance intact. Geographic diversification: The Asia Pacific region posted double-digit growth, led by Japan and China, where new product launches and expanded clinical indications contributed. The company expects mid-teens growth in China to continue, citing the diversification of its portfolio and ongoing investment in commercial capabilities. Strategic acquisitions: Recent acquisitions of SoniVie (ultrasound-based therapy for hypertension) and Intera Oncology (liver cancer therapies) are intended to strengthen the company's portfolio in targeted adjacencies. Management noted that these additions align with Boston Scientific's strategy to address large, growing end markets and complement existing franchises. Drivers of Future Performance Boston Scientific's forward outlook is anchored by continued innovation, expanded product approvals, and a focus on international growth, balanced against expected tariff and reimbursement headwinds. Expanded product indications: Management anticipates growth from regulatory approvals for new devices and expanded indications, including the expected launch of the EMPOWER leadless pacemaker and additional labeling for FARAPULSE in Japan and China. These approvals are seen as key to increasing the company's addressable market and supporting durable revenue growth. Ongoing R&D and investment: The company plans to maintain elevated investment in research and development, particularly to accelerate clinical trials and support upcoming product launches. This includes expanding clinical evidence for products such as FARAPULSE and WATCHMAN, which management believes will reinforce competitive positioning. External pressures and risk management: Tariffs and reimbursement changes—such as proposed cuts to Medicare payments for certain cardiac procedures—present headwinds. Management stated that they expect a $100 million tariff headwind for the year but intend to offset these impacts through sales mix improvements and expense discipline. They also acknowledged the need for ongoing engagement with medical societies to address reimbursement challenges. Catalysts in Upcoming Quarters Looking ahead, the StockStory team will focus on (1) the pace and commercial impact of new product launches and regulatory approvals, (2) the sustainability of double-digit growth in key international markets such as China and Japan, and (3) the company's ability to manage margin pressures from tariffs and reimbursement changes. Progress in integrating recent acquisitions and execution on clinical trial milestones will also be important indicators. Boston Scientific currently trades at $108.70, up from $103.22 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). Our Favorite Stocks Right Now When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
10-07-2025
- Business
- Globe and Mail
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
Boston Scientific 's BSX robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the WATCHMAN devices are also encouraging. The company's impressive strategic acquisitions provide a favorable opportunity for growth. Meanwhile, headwinds like currency fluctuations are concerning for its operations. In the past year, this Zacks Rank #2 (Buy) company's shares have rallied 33.6% compared with the industry and the S&P 500 composite's growth of 11.7% and 10.1%, respectively. The renowned manufacturer of medical devices and products has a market capitalization of $153.61 billion. BSX beat on earnings in each of the trailing four quarters, delivering an average surprise of 8.79%. Let us delve deeper. Upsides for BSX Stock MedSurg's Impressive Market Share Gain: Boston Scientific is consistently gaining market share within its MedSurg segment. The Endoscopy business within MedSurg is gaining from strong growth in endoluminal surgery and single-use imaging franchises, along with sustained growth of the AXIOS platform, where the company is reinvesting to drive expanded indications. Within Urology, Boston Scientific continues to expand market share globally. The company's Stone management and prostheticurology franchises are growing well, led by key launches with the TENACIO pump for the AMS 700 and continued success with the expanding LithoVue portfolio. Within Neuromodulation, Boston Scientific's pain and brain businesses are gaining traction. Within deep brain stimulation, the company expects to see improved growth in 2025, backed by the recent FDA and CE Mark approvals of the Cartesia X and HX leads. WATCHMAN, a Long-Term Growth Driver: Boston Scientific's structural heart programs are fast building momentum on the back of strong performance of the WATCHMAN left atrial appendage closure device. WATCHMAN is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally. The next generation WATCHMAN FLX and FLX Pro are capturing the global market. In the first quarter of 2025, WATCHMAN sales increased 24% year over year, with a strong contribution from the rise in concomitant procedures enabled by the new DRG, which became effective in October. Impressive Value-Adding Acquisitions: Boston Scientific's recent acquisitions have added numerous products with immense potential. The company's recently completed strategic buyouts include Bolt Medical. Earlier, BSX had acquired Cortex, an advanced AF mapping solution. The company also acquired Silk Road to broaden in the field of vascular medicine. Boston Scientific also completed the acquisition of Axonics in the fourth quarter of 2024. Sales from closed acquisitions contributed 400 basis points in the first quarter, resulting in 18.2% organic revenue growth for Boston Scientific. The company is currently looking forward to close the acquisitions of SoniVie and Intera Oncology. Downside for BSX Stock Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the past few quarters, as in the case of other important MedTech players. For 2025, the company expects a 50-basis point headwind from foreign exchange on revenues. BSX Stock's Estimate Trend The Zacks Consensus Estimate for 2025 earnings per share has remained unchanged at $2.91 in the past 30 days. The Zacks Consensus Estimate for 2025 revenues is pegged at $19.50 billion, indicating a 16.4% rise from the year-ago reported number. Other Key Picks Some other top-ranked stocks in the broader medical space are Align Technology ALGN, Abbott Laboratories ABT and Cencora COR. Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry's 9.9%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry's 3.3% decline in the past year. ALGN carries a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Abbott, currently carrying a Zacks Rank #2, has an earnings yield of 3.8% compared with the industry's 0.6%. Shares of the company have surged 129.7% compared with the industry's 35.9% gain. ABT's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.6%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 3.8%. Shares of the company have rallied 25.9% against the industry's 14.4% decline. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report
Globe and Mail
24-06-2025
- Business
- Globe and Mail
BSX Raises 2025 Financial Outlook: What's Backing It?
Boston Scientific BSX has raised its full-year 2025 guidance following robust first-quarter results and continued momentum across key growth areas. The company now anticipates net sales to grow approximately 15-17% on a reported basis (earlier 12.5-14.5%) and nearly 12-14% on an organic basis (earlier 10-12%). Full-year adjusted earnings per share are expected to be in the range of $2.87-$2.94 (previously $2.80-$2.87). On the flip side, the company expects a $200 million tariff impact in 2025, mainly in the second half. In the first quarter, the company delivered organic sales growth of 18%, exceeding the guided range of 14-16%. Adjusted EPS was $0.75, marking a 34% year-over-year increase and surpassing the forecasted $0.66-$0.68 range. This growth reflects the durability of BSX's category leadership strategy, which is powered through meaningful innovation and clinical evidence generation. Boston Scientific's Cardiology segment sales surged 31%, driven by robust growth in products such as WATCHMAN, AGENT drug-coated balloon (DCB) and FARAPULSE. WATCHMAN gained market share through rising concomitant procedures. In addition, its Electrophysiology ('EP') business experienced robust growth, with sales up 145% year over year. This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation (PFA) with FARAPULSE. Geographically, sales in the United States rose 31%, while Asia-Pacific and EMEA regions delivered 11% and 8% sales growth, respectively. Asia-Pacific growth was led by double-digit growth in Japan and high single-digit growth in China (despite volume-based procurement headwinds). BSX also plans to successfully offset the tariff impact through full-year organic sales guidance raise, targeted discretionary spending reductions and a $0.01FX benefit. Boston Scientific's Competitors Edwards Lifesciences EW reiterated its 2025 sales growth forecast of 8-10% but raised the sales dollar guidance range by $100 million, reaching $5.7-$6.1 billion. The revision was made to account for the recent movement in foreign exchange rates. Edwards continues to expect 2025 adjusted EPS to be in the range of $2.40-$2.50 despite headwinds from tariffs. This growth trajectory is driven by the continued global adoption of SAPIEN 3 Ultra RESILIA, PASCAL and EVOQUE systems. Stryker SYK raised its sales guidance for 2025, led by strong first-quarter performance, continued capital demand and robust commercial execution. The company now expects total revenues to grow in the range of 8.5-9.5% on an organic basis (previously 8-9%). However, SYK lowered its EPS guidance to $13.20-$13.45 from $13.45-$13.70, reflecting headwinds from the Inari Medical acquisition and a $200 million impact from announced tariffs. BSX Stock Price Performance, Valuation and Estimate Trend Shares of Boston Scientific have gained 33.4% in the past year compared with the industry's growth of 8.8%. The S&P 500 composite has grown 9.3% in the same period. Image Source: Zacks Investment Research From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 33.19X, above the industry's 20.83X. The Zacks Consensus Estimate for BSX's earnings has been on the rise over the past 60 days. BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Yahoo
18-06-2025
- Business
- Yahoo
Boston Scientific's Q1 Earnings Call: Our Top 5 Analyst Questions
Boston Scientific's first quarter results were met with a positive market reaction following revenue and profit that surpassed Wall Street expectations. Management credited robust growth in its cardiology portfolio and the successful execution of a category leadership strategy spanning electrophysiology, WATCHMAN, and interventional cardiology products. CEO Michael Mahoney highlighted that double-digit expansion in the U.S. and momentum in Europe and Japan helped drive operational sales growth, while new product launches and increased adoption in emerging segments, such as FARAPULSE and Axios, also contributed to performance. Is now the time to buy BSX? Find out in our full research report (it's free). Revenue: $4.66 billion vs analyst estimates of $4.57 billion (20.9% year-on-year growth, 2% beat) Adjusted EPS: $0.75 vs analyst estimates of $0.67 (11.5% beat) Revenue Guidance for Q2 CY2025 is $4.88 billion at the midpoint, above analyst estimates of $4.79 billion Management raised its full-year Adjusted EPS guidance to $2.91 at the midpoint, a 2.5% increase Operating Margin: 19.8%, up from 17.5% in the same quarter last year Organic Revenue rose 18.2% year on year (13.1% in the same quarter last year) Market Capitalization: $150.5 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Robert Marcus (JPMorgan) asked about mitigating tariff headwinds. CFO Daniel Brennan explained the offset through increased revenue and targeted cost reductions, with no plans for major manufacturing shifts. Larry Biegelsen (Wells Fargo) questioned global electrophysiology market share. CEO Michael Mahoney acknowledged strong momentum and the goal of reaching #1, particularly through investments in China and Japan. Joanne Wuensch (Citi) inquired about WATCHMAN's growth and procedural trends. Mahoney and Dr. Ken Stein cited rapid adoption of concomitant procedures and favorable clinical data as key drivers. Travis Steed (Bank of America) asked about margin sustainability. Brennan attributed margin expansion to product mix and noted that tariffs will pressure gross margin in the second half, but full-year expansion is still expected. Danielle Antalffy (UBS) raised questions on the SoniVie acquisition's timing and potential. Mahoney described the clinical trial process and anticipated a multi-year path to realizing commercial contributions. In upcoming quarters, the StockStory team will monitor (1) continued growth and market share gains in electrophysiology and WATCHMAN, (2) progress on integrating new acquisitions and the resulting product launches, and (3) the company's ability to offset tariff-related cost pressures without sacrificing margin targets. Updates on key clinical trials and regulatory milestones will also be critical to tracking Boston Scientific's strategy execution. Boston Scientific currently trades at $101.38, up from $94.97 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Yahoo
06-06-2025
- Health
- Yahoo
Pepin Heart Institute at AdventHealth Tampa becomes first in Tampa Bay to complete 1,000th WATCHMAN™ heart procedure
TAMPA, Fla., June 5, 2025 /PRNewswire/ -- The heart care experts at the Pepin Heart Institute, a part of AdventHealth Tampa, are now the first in the Tampa Bay area to complete 1,000 WATCHMAN ™ procedures, a minimally-invasive surgery that helps prevent stroke and cardiovascular death in patients with atrial fibrillation (AFib) who are at increased risk. The WATCHMAN is a device about the size of a quarter. It's implanted via catheter through a vein in the upper leg and placed in the heart's left atrial appendage, where more than 90 percent of stroke-causing clots originate in patients with non-valvular AFib. Once in place, the device creates a long-term solution for stroke prevention. "Hitting this milestone, with the 1,000th WATCHMAN procedure recently completed by Dr. Paul Gerczuk, reflects our commitment to delivering leading-edge cardiovascular care using the most advanced techniques available," said Dr. Kenneth Yamamura, a board-certified electrophysiologist at the Pepin Heart Institute. "The WATCHMAN allows us to reduce our patients' stroke risk and help them come off blood thinners over time, significantly improving their quality of life." For Gregory Kingery of Sebring, the procedure was life changing. After being diagnosed with AFib, Kingery struggled to breathe and walk. Today, he credits the WATCHMAN with giving him his life back. "There's a lot of people who don't get a second lease on life," Kingery said. "I'm grateful I did." The Pepin Heart Institute at AdventHealth Tampa is a facility with a more than 35-year legacy of bringing innovative cardiovascular care to the Tampa Bay area. The Institute was born from personal experience: In 1986, when Tampa resident Art Pepin needed a heart transplant, his only option was more than 500 miles away. After surviving his transplant, he returned home determined to improve access to heart care in his own community. That mission lives on today with his son, Tom Pepin, and granddaughter, Tina, through the Pepin Family Foundation. Together, they carry forward a multigenerational commitment to advancing heart health and expanding access to life-saving treatment. "This procedure is more than a number—it's about lives transformed," Tom Pepin said at a June 4 event celebrating the milestone surgery. "Since becoming the first hospital in Tampa to offer this groundbreaking procedure in 2015, Pepin Heart Institute has been at the forefront of cardiovascular medicine. We're honored to help people in our community live longer, fuller lives." "We're proud to carry on that legacy and ensure world-class, compassionate support is available right here in Tampa Bay," Tina Pepin added. "It's a testament to the power of vision, innovation, and whole-person care." For more than 35 years, the Pepin Heart Institute, in partnership with the Dr. Kiran C. Patel Research Institute, has offered patients early access to breakthrough therapies and technologies in a state-of-the-art, three-story facility dedicated solely to heart care. Learn more at View original content to download multimedia: SOURCE AdventHealth West Florida Division Sign in to access your portfolio
